GET DAILY SIGNALSTenaya Therapeutics (TNYA) Falls -31% Over 30 Days on Clinical and Earnings Pressure
Key Takeaways
- Tenaya Therapeutics (TNYA) has fallen roughly 31% over the trailing 30 days, sliding from about $0.59 to near $0.40 and touching a 52-week low of $0.36 intraday on October 14, 2026.
- The decline reflects an FDA clinical hold on the TN-201 gene therapy program, a second-quarter 2026 earnings miss, and broad risk-off pressure on micro-cap biotechnology names.
- The stock now trades well below its 30-day, 100-day, and 200-day moving averages, with momentum readings signaling deeply oversold conditions.
- Positive pipeline milestones — including FDA RMAT designation for TN-401 and encouraging interim data for both gene therapy programs — have not been enough to reverse the selloff.
- Tenaya ended the second quarter of 2026 with $78.1 million in cash, which the company expects will fund operations through the third quarter of 2027.
- Upcoming catalysts include fourth-quarter clinical data updates and regulatory discussions on pivotal trial plans for TN-201 and TN-401.
- For a deeper look at analyst expectations and company fundamentals, explore Tenaya's Price Targets, Earnings, and Forecast pages.
- Discover how automated strategies are tracking this and thousands of other stocks on Tickeron's Trending AI Robots page.
Company Background and Pipeline Focus
Tenaya Therapeutics is a clinical-stage biotechnology company headquartered in South San Francisco, California, focused on discovering and developing potentially curative therapies that address the underlying genetic causes of heart disease. The company's pipeline is built around three candidates: TN-201, an AAV-based gene therapy for MYBPC3-associated hypertrophic cardiomyopathy (HCM); TN-401, a gene therapy for PKP2-associated arrhythmogenic right ventricular cardiomyopathy (ARVC); and TN-301, a small-molecule HDAC6 inhibitor being explored in heart failure with preserved ejection fraction and other indications.
Tenaya is pre-revenue and relies on a combination of cash reserves and collaboration income. In 2026 it entered a research collaboration with Alnylam Pharmaceuticals (ALNY) that included a $10 million upfront payment and up to roughly $1.1 billion in potential milestone payments. Investors follow the stock primarily for binary clinical data readouts and regulatory progress across a pipeline targeting both rare genetic and more prevalent forms of cardiovascular disease. I also checked this using Tickeron’s AI Screener to see how the stock compares to others in the industry.
Recent Stock Price Moves: The Last 30 Days and Quarter
Over the last 30 days, TNYA has moved sharply lower. From a closing level near $0.59 in late September, the shares fell to roughly $0.40 by late October, a decline of approximately 31%. The steepest single-session move came on October 14, 2026, when the stock dropped about 25% on volume of more than 18 million shares, marking a 52-week intraday low of $0.36.
The longer quarterly trend has been similarly weak. After trading near a 52-week high of $1.65 earlier in the period, the stock has corrected in a sustained downtrend and now sits well below its 30-day, 100-day, and 200-day moving averages. Despite this pullback, the shares remain positive on a year-to-date basis, reflecting the strength of the run-up earlier in 2026 before sentiment turned. From what I see, this kind of volatility is common in micro-cap biotech names.
Key Drivers Behind the Recent Decline
The most significant negative catalyst was an FDA clinical hold on the MyPEAK-1 trial of TN-201, centered on protocol uniformity around complement activation monitoring and the use of complement inhibitors. Although Tenaya characterized the required changes as minor and aligned with the agency's broader guidance for AAV gene therapy programs, the hold introduced fresh regulatory uncertainty into the company's lead program.
Financial results also weighed on the stock. Second-quarter 2026 earnings, reported in early August, showed a net loss of $0.20 per share — well below the roughly $0.05 per-share loss analysts had anticipated — driven in part by a $21.8 million non-cash impairment charge tied to the termination of a manufacturing facility lease.
Finally, broader market dynamics compounded the pressure. Risk-off conditions and liquidity constraints across small-cap and pre-revenue biotech names punished TNYA even after the company announced FDA RMAT designation for TN-401 in September, a development that would typically be viewed as a positive. The resulting "sell-the-news" dynamic and profit-taking underscored how binary clinical risk and funding concerns have dominated investor sentiment.
Quarterly Context and Pipeline Progress
Over the past quarter, TNYA's decline has been part of a broader de-rating of speculative biotechnology equities rather than a single-event collapse. Earlier in the period, the stock benefited from positive interim data from the MyPEAK-1 and RIDGE-1 trials, the Alnylam collaboration, and a series of regulatory designations for TN-201 and TN-401. Those gains proved difficult to sustain as the TN-201 clinical hold, the earnings miss, and persistent questions about cash runway and future financing needs outweighed the pipeline progress.
The quarterly narrative therefore reflects a tension between a scientifically productive pipeline and a market that is demanding near-term regulatory clarity and a clearer path to value. Until pivotal trial designs and financing plans are settled, the shares have remained vulnerable to high volatility and downward pressure. I’m watching this closely as more data emerges.
What to Watch in the Months Ahead
Several factors will shape TNYA's trajectory in the coming months. The company has said it plans to provide additional RIDGE-1 and MyPEAK-1 data and an update on its regulatory discussions regarding pivotal trial plans for TN-201 and TN-401 by the end of 2026. Resolution of the TN-201 clinical hold and clarity on approvable endpoints will be central to investor confidence.
Third-quarter 2026 financial results are also expected in the near term, offering an update on the company's expense trajectory and cash position. Tenaya has guided that existing cash should support operations through the third quarter of 2027, but any signals about future financing or the pace of clinical spending will be closely watched. Broader risk appetite for small-cap biotech, interest-rate expectations, and competitive developments in the HCM and ARVC markets round out the key variables. As with all clinical-stage companies, outcomes remain uncertain, and no single catalyst guarantees a sustained move in either direction.
Exploring Tickeron AI Tools in My Research
I often turn to Tickeron’s AI Daily Buy/Sell Signals when evaluating names like this one to get a sense of automated sentiment alongside the fundamentals. The platform’s bots help surface patterns across thousands of tickers, which can be useful for spotting divergences or confirming oversold readings in volatile sectors. It has become a regular part of how I cross-check ideas before forming a view on positioning.
Disclaimer
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.
Contributor
Sergey Savastiouk, Ph.D. has a degree in Applied Mathematics from Moscow University and has extensive experience as an entrepreneur, investor, manager, and mathematician. His professional expertise is in applied mathematics, mathematical modeling, system and pattern analysis, and software and hardware system integration. He has served as the CEO of several hi-tech start-up companies and nonprofit organizations, which has given him proven capabilities in business strategy for high-tech start-up companies, market assessment, company formation, team building, product development, marketing, and sales. He has published numerous articles in journals and magazines on related fields. As a retail investor, he spent 15 years developing his proprietary trading and quantitative algorithms (now Tickeron’s A.I.), which brought him significant returns in trading the stock market. His current work and goal in founding Tickeron is to bring professional, sophisticated stock market analysis capabilities to retail investors via an easy-to-use interface.
TNYA in +5.31% Uptrend, advancing for three consecutive days on October 26, 2026
Moving higher for three straight days is viewed as a bullish sign. Keep an eye on this stock for future growth. Considering data from situations where TNYA advanced for three days, in 213 of 245 cases, the price rose further within the following month. The odds of a continued upward trend are 87%.
Technical Analysis (Indicators)
Bullish Trend Analysis
The RSI Oscillator points to a transition from a downward trend to an upward trend -- in cases where TNYA's RSI Oscillator exited the oversold zone, 33 of 38 resulted in an increase in price. Tickeron's analysis proposes that the odds of a continued upward trend are 87%.
The Stochastic Oscillator shows that the ticker has stayed in the oversold zone for 9 days. The price of this ticker is presumed to bounce back soon, since the longer the ticker stays in the oversold zone, the more promptly an upward trend is expected.
TNYA may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options.
Bearish Trend Analysis
The Momentum Indicator moved below the 0 level on September 24, 2026. You may want to consider selling the stock, shorting the stock, or exploring put options on TNYA as a result. In 70 of 77 cases where the Momentum Indicator fell below 0, the stock fell further within the subsequent month. The odds of a continued downward trend are 90%.
The Moving Average Convergence Divergence Histogram (MACD) for TNYA turned negative on September 24, 2026. This could be a sign that the stock is set to turn lower in the coming weeks. Traders may want to sell the stock or buy put options. Tickeron's A.I.dvisor looked at 45 similar instances when the indicator turned negative. In 40 of the 45 cases the stock turned lower in the days that followed. This puts the odds of success at 89%.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where TNYA declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 90%.
The Aroon Indicator for TNYA entered a downward trend on October 23, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.
Fundamental Analysis (Ratings)
The Tickeron PE Growth Rating for this company is 9 (best 1 - 100 worst), pointing to outstanding earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron Valuation Rating of 60 (best 1 - 100 worst) indicates that the company is fair valued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (1.297) is normal, around the industry mean (2.974). P/E Ratio (-0.787) is within average values for comparable stocks, (-0.899). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (9.059). Dividend Yield (0.000) settles around the average of (135.903) among similar stocks. P/S Ratio (94.340) is also within normal values, averaging (439.237).
The Tickeron Price Growth Rating for this company is 90 (best 1 - 100 worst), indicating slightly worse than average price growth. TNYA’s price grows at a lower rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron SMR rating for this company is 99 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. TNYA’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 94, placing this stock worse than average.
Notable companies
Industry description
Market Cap
High and low price notable news
Volume
Fundamental Analysis Ratings
The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows
Advertisement
General Information
Industry Biotechnology
Advertisement